Published in Cancer Weekly, June 8th, 2010
Dr. Mark A. Sirgo, President and Chief Executive Officer and Dr. Andrew L. Finn, Executive Vice President of Product Development will host the session. Global experts in pain management and the treatment of opioid dependence with first-hand experience in clinical studies of, as well as prescribing, ONSOLIS (fentanyl buccal soluble film) and buprenorphine will provide insight into the profile and benefits of both drugs. In...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.